Redeye comments on AVTECH's preliminary numbers for Q4'22 which was largely in line with our estimat...
OrderYOYO announced on Thursday, January 12th, the company’s performance during Q4-22.
Redeye states that Neonode’s patent 879 is judged not to be unpatentable – implying a crucial win fo...
Redeye is encouraged by Adverty's momentum in increasing its reach on the supply side and the increa...
Redeye comments on the news released earlier today, Wyld Networks has received a large order for its...
Redeye endorses yesterday’s news that Alzecure has chosen a candidate drug for its second project wi...
Investors House announced yesterday (11 January) that its zoning plan for Neilikkatie 17 in Tikkuril...
Redeye provides a research update following the Q1 report published by Newbury yesterday.
Q4 results due Friday, 10 February Sales +32% y-o-y on recent order momentum We cut '23e-'24e EBIT b...
Previous pre-tax profit guidance interval of DKK 500m-600m.
Redeye slightly adjusts our expectations on 2023e based on the price adjustments made by CMS in the ...
Redeye leaves an initial comment following the Q1 report published by Newbury this morning.
Q4 report due on Tuesday, 7 February We expect EBIT margin to bottom out at 9.
We raise our adjusted EBIT estimates by 6% for 2023-24, mainly as a consequence of the implementatio...
Redeye takes a positive stance towards CombinedX's acquisition of the Microsoft-focused CRM speciali...
Suominen has initiated a consultation process to close manufacturing at its Mozzate plant in Italy i...
Redeye updates its outlook on Calliditas, anticipating US launch support and the European launch ove...
Q4 report due on Monday, 23 January Discontinues unprofitable operations, '23e-'24e EBITA up 2% 11x...
Redeye comments on Genovis following today's news regarding a sublicensing of Xork to Astellas Pharm...
Redeye revisits its view of Herantis in the wake of the company’s shifted strategy toward HER-096– a...
